Europe Nuclear Medicine Market - Trends and Forecasts (2017 - 2022)

The European nuclear medicine market is expected to reach USD 4,660 million by the end of 2019, growing at a CAGR of around 10% from 2014 to 2019.

Nuclear medicine utilizes radioisotopes for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be radiopharmaceuticals. Their uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

Europe Nuclear Medicine Market-Market Dynamics

The use of nuclear medicine for diagnostic purposes is gaining importance in Europe rapidly. There has been increased use of SPECT, PET, CT and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimerdisease, coronary heart diseases, bone metastasis, different medical conditions affecting the thyroid gland, scar -tissue removal and many cancers. In Europe, treatment for thyrotoxicosis through nuclear medicine has a large share in nuclear medicine therapeutics market. Advancements in diagnostic imaging are bringing in more use of nuclear medicine.


The key driving factor for the market in Europe is the umbrella organization for nuclear medicine, the European Association for Nuclear Medicine (EANM) in Europe, which stands ready for political follow-up and professional input to guarantee patient care and safety throughout Europe. Other driving factors include:

Increasing incidence of cancer, thyroidal diseases, endocrinal diseases, and cardiac ailments

Rise in applications of SPECT and PET with advancement of technology

Growing awareness amongst physicians

Public awareness for better healthcare


Some of the factors restraining the market growth are:

Short half-life of radiopharmaceuticals

High capital investment required for development

Stringent regulatory guidelines


The market offers ample opportunities to the players in the form of:

Increasing imaging technologies

Potential radioisotopes in the pipeline

Increasing neurological applications

Increasing cyclotron-based production

The European nuclear medicine market has been segmented based on type and application. The segmentation based on type of product has been further divided based on diagnostic market and therapeutic market, wherein, the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18, and the therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications include application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.

On the basis of geography, the market has been segmented into the United Kingdom, Germany, France, Scandinavia, Italy, Spain, and the Benelux countries. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. France, UK, and Germany lead when it comes to the use of nuclear medicine.

Currently, diagnostics segment holds the largest share in nuclear medicine market, in which SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.

Some of the key players in the market are:

Cardinal Health, Inc.

GE Healthcare

IBA Group

Lantheus Medical Imaging

Nordion, Inc.

NTP Radioisotopes

Siemens Healthcare

Triad Isotope

What the Report Offers

Market definition for the European nuclear medicine market along with identification of key drivers and restraints for the market.

Market analysis for the European nuclear medicine market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the European nuclear medicine market on a regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

1. Introduction

1.1 Study deliverables

1.2 Market Definition

1.3 Sizing Units

1.4 Base Currency

1.5 Review and Forecast period years

1.6 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Econometric Forecast Model

2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

5.1 Current Market Scenario

5.2 Nuclear Medicine Applications

5.3 Technology Overview

5.4 New Developments

5.5 Industry Value chain analysis

5.6 product Lifecycle analysis

5.7 Product Benchmarking

5.8 Investment Analysis

5.9 Porter's Five Forces

5.9.1 Bargaining Power of Suppliers

5.9.2 Bargaining Power of Consumers

5.9.3 Threat to new entrants

5.9.4 Threat to substitute products and services

5.9.5 Competitive Rivalry within the industry

6. Drivers, Restraints, Opportunities, and challenges Analysis

6.1 Market Drivers

6.1.1 Increasing incidents of Cancer and Cardiac Ailments

6.1.2 Increasing SPECT and PET applications

6.1.3 Growing awareness amongst Physicians and Public usage of Advanced healthcare facilities

6.2 Market Restraints

6.2.1 Short half-life of Radiopharmaceuticals

6.2.2 High Capital Investment

6.2.3 Regulatory Guidelines

6.3 Opportunities

6.3.1 Increasing Imaging Technologies

6.3.2 Potential Radioisotopes in Pipeline

6.3.3 Increasing Neurological Applications

6.3.4 Cyclotron Based Production

6.4 Threats

6.4.1 Shutdown of Nuclear Reactors

7. Europe Nuclear Medicine Market Segmentation

7.1 Nuclear Medicine Market, by Type of Product

7.1.1 Diagnostic Market SPECT Radioisotopes Technetium-99m (TC-99m) Thallium-201 (Tl-201) Iodine (I-123) Gallium-67 (Ga-67) Others PET Radioisotopes Rubidium-82 Fluorine-18 Others

7.1.2 Therapeutics Market Alpha Emitters Radium-223 (Ra-223) Beta Emitters Iodine-131 (I-131) Samarium-153 (Sm-153) Rhenium-186 (Re-186) Lutetium-177 (Lu-177) Yttrium-90 (Y-90) Others Brachtherapy Iodine-125 (I-125) Cesium-131 (Cs-131) Palladium-103 Iridium-192 Others

7.2 Nuclear Medicine Market, by Application

7.2.1 Introduction

7.2.2 Diagnostics PET Cardiology Neurology Oncology Others SPECT Cardiology Neurology Oncology Others

7.2.3 Therapeutics Oncology Thyroid Endocrinology Others

8. Market segmentation by Geography - Europe Share and forecast

8.1 Europe

8.1.1 Introduction

8.1.2 United Kingdom

8.1.3 Germany

8.1.4 France

8.1.5 Spain

8.1.6 Italy

8.1.7 Scandinavia

8.1.8 Others

9. Competitive Landscape

9.1 Merger and acquisition analysis

9.2 New Product Launches

9.3 Agreements, Collaborations, and Partnerships

10. Key Vendor Analysis

10.1 Mallinckrodt

10.2 Lantheus Medical Imaging

10.3 IBA Group

10.4 Triad Isotope

10.5 Siemens Healthcare

10.6 NTP Radioisotopes

10.7 Cardinal Health, Inc.

10.8 GE Healthcare

10.9 Nordion, Inc.

10.10 Fujifilm Holding Corporation

11. Analyst outlook for Investment opportunities

12. Future Outlook of the market

Content are not available

Choose License Type